Coherus BioSciences, Inc.
NASDAQ:CHRS
1.3 (USD) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 257.244 | 211.042 | 326.551 | 475.824 | 356.071 | 1.556 | 1.556 | 190.106 | 30.041 | 31.106 | 2.751 | 1.899 |
| Cost of Revenue
| 162.783 | 70.083 | 57.591 | 37.667 | 17.078 | 3.235 | 160.531 | 254.44 | 212.68 | 78.224 | 31.279 | 34.886 |
| Gross Profit
| 94.461 | 140.959 | 268.96 | 438.157 | 338.993 | -1.679 | -158.975 | -64.334 | -182.639 | -47.118 | -28.528 | -32.987 |
| Gross Profit Ratio
| 0.367 | 0.668 | 0.824 | 0.921 | 0.952 | -1.079 | -102.169 | -0.338 | -6.08 | -1.515 | -10.37 | -17.371 |
| Reseach & Development Expenses
| 102.045 | 199.358 | 363.105 | 142.759 | 94.188 | 110.239 | 162.389 | 254.44 | 213.062 | 78.224 | 31.279 | 34.886 |
| General & Administrative Expenses
| 0 | 187.981 | 161.013 | 135.279 | 132.537 | 94.177 | 71.303 | 51.597 | 36.046 | 17.564 | 7.465 | 5.531 |
| Selling & Marketing Expenses
| 0 | 10.5 | 8.7 | 3.8 | 4.5 | 2.8 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 185.615 | 198.481 | 169.713 | 139.079 | 137.037 | 94.177 | 71.303 | 51.597 | 36.046 | 17.564 | 7.465 | 5.531 |
| Other Expenses
| 5.469 | 3.822 | -0.283 | 0.554 | 2.608 | 4.691 | 3.402 | -3.877 | -4.838 | -18.595 | -12.349 | 7.014 |
| Operating Expenses
| 287.66 | 397.839 | 532.818 | 281.838 | 231.225 | 204.416 | 233.692 | 306.037 | 249.108 | 95.788 | 38.744 | 40.417 |
| Operating Income
| -193.199 | -256.88 | -263.858 | 156.319 | 107.768 | -204.416 | -232.136 | -115.931 | -219.067 | -64.682 | -35.993 | -38.518 |
| Operating Income Ratio
| -0.751 | -1.217 | -0.808 | 0.329 | 0.303 | -131.373 | -149.188 | -0.61 | -7.292 | -2.079 | -13.084 | -20.283 |
| Total Other Income Expenses Net
| -45.073 | -34.874 | -23.242 | -20.612 | -14.993 | 4.691 | 3.402 | -3.877 | -4.838 | -18.595 | -12.349 | 7.014 |
| Income Before Tax
| -238.272 | -291.754 | -287.1 | 135.707 | 92.775 | -209.409 | -238.286 | -127.788 | -223.938 | -87.177 | -53.635 | -33.018 |
| Income Before Tax Ratio
| -0.926 | -1.382 | -0.879 | 0.285 | 0.261 | -134.582 | -153.14 | -0.672 | -7.454 | -2.803 | -19.497 | -17.387 |
| Income Tax Expense
| -0.38 | 34.874 | 19.222 | 3.463 | 2.942 | 4.691 | 9.44 | 0.656 | -7.352 | -15.413 | -7.056 | 8.528 |
| Net Income
| -237.892 | -326.628 | -306.322 | 132.244 | 89.833 | -209.339 | -238.17 | -127.337 | -223.26 | -87.133 | -53.635 | -33.018 |
| Net Income Ratio
| -0.925 | -1.548 | -0.938 | 0.278 | 0.252 | -134.537 | -153.066 | -0.67 | -7.432 | -2.801 | -19.497 | -17.387 |
| EPS
| -2.53 | -4.21 | -4.06 | 1.85 | 1.29 | -3.22 | -4.48 | -3.04 | -6.01 | -10.64 | -2.97 | -1.83 |
| EPS Diluted
| -2.53 | -4.21 | -4.06 | 1.62 | 1.23 | -3.22 | -4.48 | -3.04 | -6.01 | -10.64 | -2.97 | -1.83 |
| EBITDA
| -189.408 | -253.058 | -264.141 | 156.873 | 110.376 | -199.725 | -228.734 | -119.808 | -223.905 | -83.277 | -47.938 | -31.283 |
| EBITDA Ratio
| -0.736 | -1.199 | -0.809 | 0.33 | 0.31 | -128.358 | -147.001 | -0.63 | -7.453 | -2.677 | -17.426 | -16.473 |